Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia.

Radpour R, Riether C, Simillion C, Höpner S, Bruggmann R, Ochsenbein AF.

Leukemia. 2019 Mar 15. doi: 10.1038/s41375-019-0441-9. [Epub ahead of print]

PMID:
30877275
2.

T-cell-Secreted TNFα Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer.

Al Sayed MF, Amrein MA, Bührer ED, Huguenin AL, Radpour R, Riether C, Ochsenbein AF.

Cancer Res. 2019 Jan 15;79(2):346-359. doi: 10.1158/0008-5472.CAN-17-3026. Epub 2018 Nov 2.

PMID:
30389698
3.

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).

Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Swiss Group for Clinical Cancer Research (SAKK).

J Thorac Oncol. 2019 Jan;14(1):115-123. doi: 10.1016/j.jtho.2018.09.011. Epub 2018 Sep 26.

PMID:
30267838
4.

mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.

Liang SQ, Bührer ED, Berezowska S, Marti TM, Xu D, Froment L, Yang H, Hall SRR, Vassella E, Yang Z, Kocher GJ, Amrein MA, Riether C, Ochsenbein AF, Schmid RA, Peng RW.

Oncogene. 2019 Jan;38(5):622-636. doi: 10.1038/s41388-018-0479-6. Epub 2018 Aug 31.

PMID:
30171261
5.

T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.

Hilmenyuk T, Ruckstuhl CA, Hayoz M, Berchtold C, Nuoffer JM, Solanki S, Keun HC, Beavis PA, Riether C, Ochsenbein AF.

Oncoimmunology. 2017 Sep 21;7(1):e1365997. doi: 10.1080/2162402X.2017.1365997. eCollection 2017.

6.

CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.

Al Sayed MF, Ruckstuhl CA, Hilmenyuk T, Claus C, Bourquin JP, Bornhauser BC, Radpour R, Riether C, Ochsenbein AF.

Blood. 2017 Jul 20;130(3):297-309. doi: 10.1182/blood-2016-12-756585. Epub 2017 May 11.

7.

CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia.

Riether C, Schürch CM, Bührer ED, Hinterbrandner M, Huguenin AL, Hoepner S, Zlobec I, Pabst T, Radpour R, Ochsenbein AF.

J Exp Med. 2017 Feb;214(2):359-380. doi: 10.1084/jem.20152008. Epub 2016 Dec 28.

8.

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2017 May;18(3):303-309. doi: 10.1016/j.cllc.2016.11.007. Epub 2016 Nov 23.

PMID:
27993482
9.

TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis.

Zysset D, Weber B, Rihs S, Brasseit J, Freigang S, Riether C, Banz Y, Cerwenka A, Simillion C, Marques-Vidal P, Ochsenbein AF, Saurer L, Mueller C.

Nat Commun. 2016 Oct 20;7:13151. doi: 10.1038/ncomms13151.

10.

Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling.

Riether C, Schürch CM, Flury C, Hinterbrandner M, Drück L, Huguenin AL, Baerlocher GM, Radpour R, Ochsenbein AF.

Sci Transl Med. 2015 Jul 29;7(298):298ra119. doi: 10.1126/scitranslmed.aab1740.

PMID:
26223302
11.

IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.

Mager LF, Riether C, Schürch CM, Banz Y, Wasmer MH, Stuber R, Theocharides AP, Li X, Xia Y, Saito H, Nakae S, Baerlocher GM, Manz MG, McCoy KD, Macpherson AJ, Ochsenbein AF, Beutler B, Krebs P.

J Clin Invest. 2015 Jul 1;125(7):2579-91. doi: 10.1172/JCI77347. Epub 2015 May 26.

12.

CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis.

Galli S, Zlobec I, Schürch C, Perren A, Ochsenbein AF, Banz Y.

Leuk Res. 2015 Jul;39(7):749-56. doi: 10.1016/j.leukres.2015.04.007. Epub 2015 Apr 20.

PMID:
25943033
13.

Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2015 Sep;16(5):358-65. doi: 10.1016/j.cllc.2015.02.007. Epub 2015 Mar 5.

PMID:
25843489
14.

Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells.

Riether C, Gschwend T, Huguenin AL, Schürch CM, Ochsenbein AF.

Leukemia. 2015 Aug;29(8):1781-5. doi: 10.1038/leu.2015.26. Epub 2015 Feb 4. No abstract available.

15.

Microbiota-derived compounds drive steady-state granulopoiesis via MyD88/TICAM signaling.

Balmer ML, Schürch CM, Saito Y, Geuking MB, Li H, Cuenca M, Kovtonyuk LV, McCoy KD, Hapfelmeier S, Ochsenbein AF, Manz MG, Slack E, Macpherson AJ.

J Immunol. 2014 Nov 15;193(10):5273-83. doi: 10.4049/jimmunol.1400762. Epub 2014 Oct 10.

16.

Regulation of hematopoietic and leukemic stem cells by the immune system.

Riether C, Schürch CM, Ochsenbein AF.

Cell Death Differ. 2015 Feb;22(2):187-98. doi: 10.1038/cdd.2014.89. Epub 2014 Jul 4. Review.

17.

Cytotoxic CD8+ T cells stimulate hematopoietic progenitors by promoting cytokine release from bone marrow mesenchymal stromal cells.

Schürch CM, Riether C, Ochsenbein AF.

Cell Stem Cell. 2014 Apr 3;14(4):460-72. doi: 10.1016/j.stem.2014.01.002. Epub 2014 Feb 20.

18.

Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.

Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E.

Cancer Immunol Immunother. 2014 Apr;63(4):381-94. doi: 10.1007/s00262-013-1516-5. Epub 2014 Feb 2.

PMID:
24487961
19.

Dendritic cell-based immunotherapy for myeloid leukemias.

Schürch CM, Riether C, Ochsenbein AF.

Front Immunol. 2013 Dec 31;4:496. doi: 10.3389/fimmu.2013.00496. Review.

20.

Interferons in hematopoiesis and leukemia.

Schürch CM, Riether C, Ochsenbein AF.

Oncoimmunology. 2013 Jun 1;2(6):e24572. Epub 2013 Apr 16.

21.

Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.

Schürch C, Riether C, Amrein MA, Ochsenbein AF.

J Exp Med. 2013 Mar 11;210(3):605-21. doi: 10.1084/jem.20121229. Epub 2013 Feb 11.

22.

From "magic bullets" to specific cancer immunotherapy.

Riether C, Schürch C, Ochsenbein AF.

Swiss Med Wkly. 2013 Jan 23;143:w13734. doi: 10.4414/smw.2013.13734. eCollection 2013. Review.

23.

Modulating CD27 signaling to treat cancer.

Riether C, Schürch C, Ochsenbein AF.

Oncoimmunology. 2012 Dec 1;1(9):1604-1606.

24.

CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth.

Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF.

Cancer Res. 2012 Jul 15;72(14):3664-76. doi: 10.1158/0008-5472.CAN-11-2791. Epub 2012 May 24.

25.

CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression.

Schürch C, Riether C, Matter MS, Tzankov A, Ochsenbein AF.

J Clin Invest. 2012 Feb;122(2):624-38. doi: 10.1172/JCI45977. Epub 2012 Jan 9.

26.

Destruction of lymphoid organ architecture and hepatitis caused by CD4+ T cells.

Matter MS, Hilmenyuk T, Claus C, Marone R, Schürch C, Tinguely M, Terracciano L, Luther SA, Ochsenbein AF.

PLoS One. 2011;6(9):e24772. doi: 10.1371/journal.pone.0024772. Epub 2011 Sep 23.

27.

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.

Ochsenbein AF, Schubert AD, Vassella E, Mariani L.

J Neurooncol. 2011 Jun;103(2):343-51. doi: 10.1007/s11060-010-0395-2. Epub 2010 Sep 21.

28.

Chronic myelogenous leukemia maintains specific CD8(+) T cells through IL-7 signaling.

Mumprecht S, Schürch C, Scherrer S, Claus C, Ochsenbein AF.

Eur J Immunol. 2010 Oct;40(10):2720-30. doi: 10.1002/eji.201040404.

29.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.

J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.

PMID:
20439646
30.

Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.

Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek Mv, Radbruch A, Lévy F, Lambert PH, Siegrist CA, Restifo NP, Löhning M, Ochsenbein AF, Nabel GJ, Pinschewer DD.

Nat Med. 2010 Mar;16(3):339-45. doi: 10.1038/nm.2104. Epub 2010 Feb 7.

31.

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF.

Blood. 2009 Aug 20;114(8):1528-36. doi: 10.1182/blood-2008-09-179697. Epub 2009 May 6.

32.

Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.

Mumprecht S, Claus C, Schürch C, Pavelic V, Matter MS, Ochsenbein AF.

Blood. 2009 May 7;113(19):4681-9. doi: 10.1182/blood-2008-05-156471. Epub 2009 Feb 27.

33.

CTL induction by cross-priming is restricted to immunodominant epitopes.

Pavelic V, Matter MS, Mumprecht S, Breyer I, Ochsenbein AF.

Eur J Immunol. 2009 Mar;39(3):704-16. doi: 10.1002/eji.200838901.

34.

Natural antibodies target virus-antibody complexes to organized lymphoid tissue.

Matter MS, Ochsenbein AF.

Autoimmun Rev. 2008 Jun;7(6):480-6. doi: 10.1016/j.autrev.2008.03.018. Epub 2008 Apr 23. Review.

PMID:
18558366
35.

Early clinical trial experience with vaccine therapies in non-small-cell lung cancer.

Ho C, Ochsenbein AF, Gautschi O, Davies AM.

Clin Lung Cancer. 2008 Feb;9 Suppl 1:S20-7. Review.

PMID:
18540531
36.

CD4+ T cell help improves CD8+ T cell memory by retained CD27 expression.

Matter MS, Claus C, Ochsenbein AF.

Eur J Immunol. 2008 Jul;38(7):1847-56. doi: 10.1002/eji.200737824.

37.

Decreased tumor surveillance after adoptive T-cell therapy.

Matter M, Pavelic V, Pinschewer DD, Mumprecht S, Eschli B, Giroglou T, von Laer D, Ochsenbein AF.

Cancer Res. 2007 Aug 1;67(15):7467-76.

38.

[Extraordinary manifestation of a gastric carcinoma by leptomeningeal carcinomatosis and spinal metastasis].

Cresto N, Barth A, Arnold M, Weimann R, Gschossmann J, Ochsenbein AF, Kolotas C, Peter HJ, Schiemann U.

Med Klin (Munich). 2007 Mar 15;102(3):255-8. German.

39.

Elimination of chronic viral infection by blocking CD27 signaling.

Matter M, Odermatt B, Yagita H, Nuoffer JM, Ochsenbein AF.

J Exp Med. 2006 Sep 4;203(9):2145-55. Epub 2006 Aug 21.

40.

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

Mumprecht S, Matter M, Pavelic V, Ochsenbein AF.

Blood. 2006 Nov 15;108(10):3406-13. Epub 2006 Jul 27.

41.

Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL.

Matter M, Mumprecht S, Pinschewer DD, Pavelic V, Yagita H, Krautwald S, Borst J, Ochsenbein AF.

Eur J Immunol. 2005 Nov;35(11):3229-39.

42.

Immunological ignorance of solid tumors.

Ochsenbein AF.

Springer Semin Immunopathol. 2005 Jun;27(1):19-35. Epub 2005 Jan 27. Review.

PMID:
15965711
43.

CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients.

Ochsenbein AF, Riddell SR, Brown M, Corey L, Baerlocher GM, Lansdorp PM, Greenberg PD.

J Exp Med. 2004 Dec 6;200(11):1407-17.

44.

Outcome of the antibody response: a question of antigen dose and distribution.

Fehr T, Ochsenbein AF.

Trends Immunol. 2004 Apr;25(4):165-6; author reply 167-8. No abstract available.

PMID:
15039040
45.

Principles of tumor immunosurveillance and implications for immunotherapy.

Ochsenbein AF.

Cancer Gene Ther. 2002 Dec;9(12):1043-55. Review.

46.

Quantification of fetomaternal hemorrhage by fluorescence microscopy is equivalent to flow cytometry.

Ochsenbein-Imhof N, Ochsenbein AF, Seifert B, Huch A, Huch R, Zimmermann R.

Transfusion. 2002 Jul;42(7):947-53. Erratum in: Transfusion. 2004 Aug;44(8):1270.

PMID:
12375669
47.

Neutralizing antiviral antibody responses.

Zinkernagel RM, LaMarre A, Ciurea A, Hunziker L, Ochsenbein AF, McCoy KD, Fehr T, Bachmann MF, Kalinke U, Hengartner H.

Adv Immunol. 2001;79:1-53. Review. No abstract available.

PMID:
11680006
48.

Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine.

Pinschewer DD, Ochsenbein AF, Fehr T, Zinkernagel RM.

Transplantation. 2001 Aug 27;72(4):712-9.

PMID:
11544436
49.

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.

Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM.

Nature. 2001 Jun 28;411(6841):1058-64. Erratum in: Nature 2001 Sep 13;413(6852):183.

PMID:
11429607
50.

Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells.

Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes RE, Melief CJ, Hengartner H, Zinkernagel RM.

J Immunol. 2001 Mar 15;166(6):3678-87.

Supplemental Content

Loading ...
Support Center